27336882|t|Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections
27336882|a|Neutralizing anti-interferon-γ autoantibody (nAIGA)-associated immunodeficiency is an emerging medical issue worldwide. In the present study, we describe and discuss the clinical features and outcomes of patients with nAIGAs and disseminated infections by nontuberculous mycobacteria (dNTM).We thoroughly reviewed the medical records of all patients. Microorganisms and nAIGAs were identified using previously described methods with modifications. All data were calculated and analyzed using SPSS software .Among 46 adult patients with dNTM infections, we identified 45 cases (97.8%) with nAIGAs. The average patient age was 58.6 years, and there was no sex predominance. Cervical lymphadenitis (81.8%) was the most common clinical manifestation. Endocrine disorder was the leading comorbidity (7 cases). Malignancies were found in 4 patients, and all of the malignancies originated from the T-cell / macrophage lineage. More than half of the identifiable isolates were slow-growing NTMs. Twenty-eight (62.2%) and 18 (40.0%) patients had a history of zoster and salmonellosis, respectively. A high proportion of patients with recurrent episodes of NTM infection or a history of zoster and dNTM infection had initial nAIGA titers ≥10 dilution (P < 0.05). Twenty-seven patients (60.0%) required long-term antimycobacterial therapy and had at least 1 episode of recurrent NTM disease. No mortality was related to dNTM infection .In Taiwan, nAIGAs are a recently recognized mechanism of dNTM infection. Long term of antibiotic treatment and adherence to medical advice are necessary to improve the clinical outcome of patients with nAIGAs.
27336882	0	8	Clinical	T080	C0205210
27336882	9	23	manifestations	T169	C0205319
27336882	25	31	course	T079	C0750729
27336882	37	56	outcome of patients	T078	C1547647
27336882	62	107	neutralizing anti-interferon-γ autoantibodies	T116,T129	C0004358
27336882	112	124	disseminated	T082	C0205221
27336882	125	153	nontuberculous mycobacterial	T007	C1265234
27336882	154	164	infections	T046	C3714514
27336882	165	208	Neutralizing anti-interferon-γ autoantibody	T116,T129	C0004358
27336882	210	215	nAIGA	T116,T129	C0004358
27336882	228	244	immunodeficiency	T047	C0021051
27336882	260	273	medical issue	T058	C0199168
27336882	274	283	worldwide	T078	C0043236
27336882	300	305	study	T062	C2603343
27336882	335	352	clinical features	T033	C3810252
27336882	357	365	outcomes	T033	C1333602
27336882	369	377	patients	T101	C0030705
27336882	383	389	nAIGAs	T116,T129	C0004358
27336882	394	406	disseminated	T082	C0205221
27336882	407	417	infections	T046	C3714514
27336882	421	448	nontuberculous mycobacteria	T007	C1265234
27336882	450	454	dNTM	T007	C1265234
27336882	483	498	medical records	T201	C0551625
27336882	506	514	patients	T101	C0030705
27336882	516	530	Microorganisms	T001	C0445623
27336882	535	541	nAIGAs	T116,T129	C0004358
27336882	547	557	identified	T080	C0205396
27336882	575	584	described	T078	C1552738
27336882	642	650	analyzed	T062	C0936012
27336882	657	670	SPSS software	T170	C0037589
27336882	687	695	patients	T101	C0030705
27336882	701	705	dNTM	T007	C1265234
27336882	706	716	infections	T046	C3714514
27336882	721	731	identified	T080	C0205396
27336882	754	760	nAIGAs	T116,T129	C0004358
27336882	774	781	patient	T101	C0030705
27336882	816	818	no	T033	C1513916
27336882	819	822	sex	T032	C1522384
27336882	823	835	predominance	T033	C0243095
27336882	837	859	Cervical lymphadenitis	T047	C0149642
27336882	888	896	clinical	T080	C0205210
27336882	897	910	manifestation	T169	C0205319
27336882	912	930	Endocrine disorder	T047	C0014130
27336882	947	958	comorbidity	T078	C0009488
27336882	970	982	Malignancies	T191	C4282132
27336882	999	1007	patients	T101	C0030705
27336882	1024	1036	malignancies	T191	C4282132
27336882	1057	1063	T-cell	T025	C0039194
27336882	1066	1076	macrophage	T025	C0024432
27336882	1077	1084	lineage	T078	C0282637
27336882	1121	1129	isolates	T123	C1764827
27336882	1135	1147	slow-growing	T033	C4086857
27336882	1148	1152	NTMs	T007	C1265234
27336882	1190	1198	patients	T101	C0030705
27336882	1216	1222	zoster	T047	C0019360
27336882	1227	1240	salmonellosis	T047	C0036117
27336882	1263	1273	proportion	T081	C1709707
27336882	1277	1285	patients	T101	C0030705
27336882	1291	1300	recurrent	T079	C2945760
27336882	1313	1316	NTM	T007	C1265234
27336882	1317	1326	infection	T046	C3714514
27336882	1343	1349	zoster	T047	C0019360
27336882	1354	1358	dNTM	T007	C1265234
27336882	1359	1368	infection	T046	C3714514
27336882	1381	1393	nAIGA titers	T059	C0474521
27336882	1432	1440	patients	T101	C0030705
27336882	1468	1485	antimycobacterial	T121	C0360390
27336882	1486	1493	therapy	T061	C0087111
27336882	1524	1533	recurrent	T079	C2945760
27336882	1534	1537	NTM	T007	C1265234
27336882	1538	1545	disease	T047	C0012634
27336882	1575	1579	dNTM	T007	C1265234
27336882	1580	1589	infection	T046	C3714514
27336882	1594	1600	Taiwan	T083	C0039260
27336882	1602	1608	nAIGAs	T116,T129	C0004358
27336882	1635	1644	mechanism	T169	C0441712
27336882	1648	1652	dNTM	T007	C1265234
27336882	1653	1662	infection	T046	C3714514
27336882	1677	1697	antibiotic treatment	T061	C0338237
27336882	1702	1711	adherence	T169	C1510802
27336882	1715	1729	medical advice	T033	C1386497
27336882	1759	1767	clinical	T080	C0205210
27336882	1768	1787	outcome of patients	T078	C1547647
27336882	1793	1799	nAIGAs	T116,T129	C0004358